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Prognosis of younger and older patients with early breast cancer
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Summary The use ofmammography in recent years has resulted in an increase in the detection of small breast
cancers. The beneficial effects of early detection on breast cancer mortality seem to differ with age. To obtain
more insight into this matter we studied the long-term prognosis of patients with early invasive breast cancers
(TI) in three age groups: 144 patients of age 40-49, 402 patients of age 50-69 and 192 patients 70 years or
older at diagnosis. In all age groups, patients with a tumour of 1 cm or less have a longer breast cancer specific
survival than patients with a tumour larger than 2 cm. The survival advantage in the case of tumours of a size
rounded to 1.5 cm compared with tumours larger than 2 cm in the under age 50 group was marginal (and not
significant). However, older patients with tumours of this size do have a significantly improved survival. It is
more difficult to improve survival in younger patients through early detection, partly because of an apparent
early metastatic potential of their tumours. A reduction in breast cancer mortality might be expected in women
younger than 50 years of age only if a substantial proportion of the invasive cancers are detected before their
size exceeds 1 cm.
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In recent years an increase in the diagnosis of early stage and
small breast cancers has been reported (Miller et al., 1993;
Nab et al., 1993). This will be mainly due to the substantial
increase in the use of mammography for screening purposes
or case finding.
Randomised trials have shown that advanced detection by
mammographic screening in women 50 years of age or older
can result in a reduction of breast cancer mortality (Hurley
and Kaldor, 1992; Fletcher et al., 1993). The benefit of
mammographic screening in younger women is not clear
(Fletcher et al., 1993). This may be owing to factors relating
to the screening process itself, such as the sensitivity of the
mammographic screening test and the frequency of screening.
However, an explanation may also be found in the biology of
the tumour. To provide insight into the nature of breast
cancer, survival curves by age group and stage of the tumour
are compared (Tabiar et al., 1993; Byrne et al., 1994). A clear
trend of increased survival with decreasing size is demon-
strated in all age groups. However, small tumours detected by
screening mammography may have a lower malignant
potential than small cancers detected by the woman herself
(Klemi et al., 1992; Tabar et al., 1992). The malignant
potential of breast cancers varies considerably between
tumours, one factor being differences in growth rate (Peer
et al., 1993). Slow-growing tumours have a longer mammo-
graphically detectable preclinical phase. Therefore the like-
lihood of being detected at screening is greater for slow-
growing than for faster growing tumours ('length -time
bias'). Consequently, a small invasive tumour detected by
screening might have a better prognosis than a clinically
diagnosed cancer of the same size. To study the prognosis of
small breast cancers, it is therefore important to take account
of the mode of detection, i.e. clinically diagnosed vs screen
detected. Since 1975 in Nijmegen a biennial mammographic
screening programme has been conducted for women over
age 35 at the start of the project (Peer et al., 1994). The
follow-up of breast cancer patients, either clinically diagnosed
or detected at a screening examination, provides an
opportunity to study the breast cancer specific survival of
the patients over an 18 year period, in particular the survival
of those with invasive tumours 2 cm or less in size (TI).
Patients and methods
Since 1975, data on all Nijmegen patients diagnosed as
having breast cancer in either one of the two Nijmegen
hospitals have been carefully recorded by the local cancer
registry of the Departments of Diagnostic Radiology and
Pathology of the Nijmegen University Hospital and of the
Canisius Wilhelmina Hospital. On record at the end of 1992
were 1333 patients, 40 years of age or older, diagnosed with
primary breast cancer. Patients with lobular carcinomas in
situ were not included because they are not treated as breast
cancer patients. Cancers were detected either in the screened
population at a screening examination (n=538) or in the
interval between the scheduled examinations, or among non-
participants of the programme or before the first screening
invitation.
Tumour size of invasive lesions was determined mammo-
graphically. If the diameter could not be assessed mammo-
graphically, the histologically determined diameter was
substituted (in 10% of the measurements). Tumour size was
available in all but 19 of the invasive cases. There was a clear
tendency to round measurements to the nearest 0.5 cm.
Therefore we used the following categories of tumour size:
1 cm or less, 1.5 cm, 2cm, 2.5-4.5 cm, 5 cm or larger.
The vital status of the Nijmegen breast cancer patients was
acquired from the local registrar's office. At the end of 1993,
478 of the 1333 patients had died. All clinical information on
these patients was gathered to classify the cause of death, i.e.
either breast cancer or another cause. Breast cancer was
considered to be the underlying cause of death when distant
metastases had been reported before death and competing
causes of death could be ruled out. For ten patients the cause
of death could not be assessed. Five of them were diagnosed
with early invasive breast cancer, i.e. involving a tumour
2 cm or less in diameter.
Breast cancer specific survival curves obtained with the
life-table method (Lee, 1980), were calculated for patients
diagnosed with in situ ductal cancers and invasive tumours by
size groups and for three age groups: 40-49, 50-69, ) 70
years of age at diagnosis. Deaths from causes other than
breast cancer were treated as censored observations in the
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survival analysis. The survival advantage with decreasing size
was expressed as the ratio of the hazards of dying from
breast cancer. Adjustment for the detection mode, i.e. screen-
detected or clinically diagnosed, was accomplished with a
proportional hazards regression analysis, applied by age
group (Lee, 1980).
0.2
Results
Among the 260 younger patients, being 40 -49 years at
diagnosis, 144 patients were diagnosed with a small (2 cm or
less) invasive breast tumour. Of the 672 patients in the 50-69
age group, 402 patients had a small invasive tumour and in
the older age group (> 70 years) 401 patients were diagnosed,
of whom 192 had a small invasive tumour.
The breast cancer survival curves by size ofthe tumour for
each of the three age groups are displayed in Figures 1-3.
The 5-, 10- and 15 year breast cancer specific survival rates
for younger patients (40-49 years) diagnosed with a small
invasive tumour of 2 cm or less were 88%, 75% and 66%
respectively. The corresponding survival percentages for
patients in the 50-69 age group were 92%, 78% and 73%
respectively. In the oldest age group (,>70 years) 90% and
83% of the patients did not die from breast cancer within 5
and 10 years respectively, after diagnosis. The number of
older patients at risk of dying from breast cancer after 15
years of follow-up was too small to calculate the 15 year
breast cancer specific survival for the >70 age group. Table I
shows the relative hazards of death from breast cancer for
patients with small invasive cancers (<2 cm), relative to the
hazard of the 2.5-4.5 cm size group for the different age
categories. Only in the oldest age group (>70 years) is there
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Figure 1 Breast cancer survival for patients 40-49 years of age
at diagnosis with DCIS and invasive breast cancer by tumour size.
Between parentheses: number of breast cancer deaths/number of
breast cancer patients. *, DCIS (0/37); 0, < cm (5/39); *,
1.5cm (8/49); D1, 2cm (15/56); A, 2.5-4.5 cm (17/58); A, 5cm
(9/17).
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Figure 3 Breast cancer survival for patients >70 years of age at
diagnosis with DCIS and invasive breast cancer by tumour size.
Between parentheses: number of breast cancer deaths/number of
breast cancer patients. 0, DCIS (0/22); 0, < cm (3/56); *,
1.5cm (8/59); r, 2cm (10/74); A, 2.5-4.5cm (28/131); A,
>5 cm (20/40).
an indication that patients with tumours of a size rounded to
2 cm have a better prognosis than patients with tumours
2.5-4.5 cm in size. The survival advantage for patients with
tumours of a size rounded to 1.5 cm (compared with tumours
of 2.5-4.5 cm) in the under 50 age group was marginal (and
not significant). However, patients with tumours of this size
in the above 50 age groups have a significantly improved
survival. In all age groups patients with tumours of 1 cm or
less have a better survival than patients with tumours larger
than 2 cm.
Part of the survival advantage of the patients with small
invasive tumours might be explained by a more favourable
biology of the screen-detected small tumours ('length-time
bias'). In younger women 35% (50/144) of the small invasive
tumours (,<2 cm) were detected at a screening examination.
In the 50- to 69-year-old age group this percentage was 59%
(238/402) and in the oldest age group 46% (89/192). To
adjust for the possible confounding effect of detection mode,
a proportional hazards model was employed that incorpo-
rates size and the mode of detection, that is, screen-detected
or clinically diagnosed (Table II). The results show that the
survival advantages for patients with tumours of 2 cm or less
(compared with larger tumours) decrease only marginally.
Table I Hazard ratio of dying from breast cancer for patients
diagnosed with early invasive breast cancer (,<2 cm) with reference
to patients in the same age group with larger invasive tumours (2.5-
4.5 cm); 95% confidence intervals are given in parentheses
Age at diagnosis (years)
40-49 50-69 >70
Tumour size (cm)
I1cm 0.37 0.26 0.17
(0.14- 1.00) (0.15-0.45) (0.05-0.55)
1.5 0.56 0.35 0.44
(0.24- 1.31) (0.20-0.61) (0.20-0.98)
2 0.81 0.88 0.51
(0.40- 1.61) (0.57- 1.38) (0.24- 1.05)
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Figure 2 Breast cancer survival for patients 50-69 years of age
at diagnosis with DCIS and invasive breast cancer by tumour size.
Between parentheses: number of breast cancer deaths/number of
breast cancer patients. 0, DCIS (1/65); 0, < 1 cm (17/155); *,
1.5cm (18/130); C, 2cm (33/115); A, 2.5-4.5cm (47/148); A,
>5 cm (25/52).
Table II Hazard ratio of dying from breast cancer for patients
diagnosed with early invasive breast cancer (<2 cm) with reference
to patients in the same age group with larger invasive tumours (2.5-
4.5 cm), 95% adjusted for detection mode (screen-detected or
clinically diagnosed); confidence intervals are given in parentheses
Age at diagnosis (years)
40-49 50-69 >e70
Tumour size (cm)
<1 cm 0.38 0.31 0.21
(0.14- 1.02) (0.17-0.56) (0.06-0.71)
1.5 0.58 0.40 0.53
(0.25- 1.35) (0.23-0.69) (0.23-1.21)
2 0.82 0.94 0.56
(0.41 -1.64) (0.60- 1.48) (0.27- 1.17)
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Discussion
The purpose of mammographic screening is to detect cancers
early in their development. However, a lower malignant
potential of screen-detected cancers may limit the effective-
ness of screening in saving lives. Few data are currently
available on the prognosis of patients with small breast
cancers, particularly of those detected at screening.
In our study we confirmed, age specifically, the good
prognosis of patients with cancers 1 cm or smaller, as was
demonstrated in other studies (Rosen et al., 1989; Rosner and
Lane, 1990; Tabfar et al., 1993; Byrne et al., 1994). In the
youngest age group only 13% of patients with a tumour
diameter of 1 cm or less died ofbreast cancer within 10 years.
Similarly, in the older age groups these failure rates were only
14% and 6% respectively.
On the other hand, the survival advantage for patients
with early breast cancers larger than 1 cm differs with age. In
the 40-49 age group no significant better breast cancer-
specific survival could be demonstrated for patients with a
tumour 1.5 or 2 cm in diameter compared with that of
patients with a larger tumour of 2.5-4.5 cm. In this age
group a substantially better survival is gained only in cases
where the tumour is 1 cm or less. For women in the age
group 50-69 at diagnosis the break for a better survival is at
1.5 cm tumour size, rising to 2 cm for the >70 age group,
compared with the survival ofpatients having larger tumours.
Thus it seems to be more difficult to improve survival in
younger patients. A similar conclusion was reached on the
basis of the survival results in the Breast Cancer Detection
Demonstration Project (BCDDP) (Byrne et al., 1994). In the
BCDDP this finding was explained by a higher breast cancer
survival rate of younger women with a larger tumour
compared with that of older women having a tumour of
the same size.
This differential effect of age on breast cancer-specific
survival of patients with small tumours could explain why it
is more difficult to achieve a beneficial effect on breast cancer
mortality in women aged 40-49 by mammographic screen-
ing. While on the one hand to gain survival advantage in this
age group tumours have to be detected when they are very
small, on the other hand it is more difficult to spot small
malignant tumours in these patients, probably because of
their frequently observed dense breast tissue (Ciatto and
Zappa, 1993).
In our study, cancers of a diameter of 1.5 cm or less
diagnosed in younger women have a greater potential for
fatality than tumours of the same size in older women. This
may be partly explained by an earlier metastatic spread
indicated by more frequent axillary lymph node involvement.
Since 1981, the axillary lymph nodes have been routinely
Table HI Axillary lymph node involvement by age and size
(invasive tumours only)
Age at diagnosis (years)
40-49 50-69 .70
Tumour size (cm)
<_ I 42%(n=26) 15%(n= 100) 25%(n=36)
1.5 62%(n =39) 30%(n=79) 21%(n= 34)
2 45%(n =38) 43%(n=63) 38%(n =45)
2.5-4.5 64%(n=39) 54%(n =99) 58%(n=78)
)5 91%(n=11) 80%(n=30) 78%(n=23)
examined histologically in the two Nijmegen hospitals. Cross-
classification of tumour size and lymph node status for the
calendar period 1981-92 (see Table III) shows that younger
patients with a tumour of 1.5 cm or less more frequently had
lymph node metastasis than older patients with a tumour of
the same size. Even after adjustment for nodal involvement in
a proportional hazards model, there is still an indication that
younger patients with a 1.5 cm or smaller tumour are at
greater risk of dying from breast cancer than women in the
age groups 50-69 and >70 [hazard ratio 2.7 (P=0.07) and
7.6 (P=0.06) respectively]. One explanation may be that
nodal involvement in older patients is biologically less
important regarding risk of distant metastasis compared
with node-positive younger patients. This is in line with the
recently formulated theory of Hellman (Hellman, 1994).
Our results indicate that a reduction in breast cancer
mortality might be expected in women younger than 50 years
of age only if a substantial proportion of the invasive cancers
are detected before their size exceeds 1 cm. However, this
target is not achieved by film-screen mammography (Peer et
al., 1994). The development of new technologies, such as
digital mammography and magnetic resonance imaging,
might offer better prospects in this regard. It is also
important that small invasive tumours rather than ductal
carcinomas in situ are detected at screening, as the proportion
of in situ tumours that progress to a life-threatening disease is
uncertain.
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